Editor’s Note: Guest writer Martin Perry attended the FDA’s advisory panel on digital pathology conducted earlier this month. He is CEO of The Perry Group and has extensive experience in imaging and healthcare. He offers his insights from the FDA proceedings on digital pathology imaging. DIGITAL PATHOLOGY CONTINUES to gain acceptance at a steady but …
FDA Advisory Panel Convenes To Assess Whole Slide Imaging Read More »
